Abstract
Clinical lipidomics is a new extension of lipidomics to study lipid profiles, pathways, and networks by characterizing and quantifying the complete lipid molecules in cells, biopsy, or body fluids of patients. It undoubtfully has more values if lipidomics can be integrated with the data of clinical proteomic, genomic, and phenomic profiles. A number of challenges, e.g., instability, specificity, and sensitivity, in lipidomics have to be faced and overcome before clinical application. The association of lipidomics data with gene expression and sequencing of lipid-specific proteins/enzymes should be furthermore clarified. Therefore, clinical lipidomics is expected to be more stable during handling, sensitive in response to changes, specific for diseases, efficient in data analyses, and standardized in measurements, in order to meet clinical needs. Clinical lipidomics will become a more important approach in clinical applications and will be the part of “natural” measures for early diagnosis and progress of disease. Thus, clinical lipidomics will be one of the most powerful approaches for disease-specific diagnosis and therapy, once the mystery of lipidomic profiles and metabolic enzymes is deciphered.
This is a preview of subscription content, log in via an institution to check access.
Change history
29 August 2019
The article Is the clinical lipidomics a potential goldmine?, written by Linlin Zhang, Xianlin Han and Xiangdong Wang, was originally published electronically on the publisher���s internet portal (currently SpringerLink) on 21 July 2018 with open access. With the author(s)��� decision to step
References
Han X. Lipidomics for studying metabolism. Nat Rev Endocrinol. 2016;12(11):668–79.
Kim WS, Jary E, Pickford R, He Y, Ahmed RM, Piguet O, et al. Lipidomics analysis of behavioral variant frontotemporal dementia: a scope for biomarker development. Front Neurol. 2018;28(9):104.
Lv J, Zhang L, Yan F, Wang X. Clinical lipidomics: a new way to diagnose human diseases. Clin Transl Med. 2018;7(1):12.
Lv J, Gao D, Zhang Y, Wu D, Shen L, Wang X. Heterogeneity of lipidomic profiles among lung cancer subtypes of patients. J Cell Mol Med. 2018. https://doi.org/10.1111/JCMM.13782.
Postle AD. Lipidomics. Curr Opin Clin Nutr Metab Care. 2012;15(2):127–33.
Vaz FM, Pras-Raves M, Bootsma AH, van Kampen AH. Principles and practice of lipidomics. J Inherit Metab Dis. 2015;38(1):41–52.
Wang X. New biomarkers and therapeutics can be discovered during COPD-lung cancer transition. Cell Biol Toxicol. 2016;32(5):359–61.
Wang X. Clinical trans-omics: an integration of clinical phenomes with molecular multiomics. Cell Biol Toxicol. 2018;34(3):163–6.
Xu M, Wang X. Critical roles of mucin-1 in sensitivity of lung cancer cells to tumor necrosis factor-alpha and dexamethasone. Cell Biol Toxicol. 2017;33(4):361–71.
Yang K, Han X. Lipidomics: techniques, applications, and outcomes related to biomedical sciences. Trends Biochem Sci. 2016;41(11):954–69.
Yang L, Li M, Shan Y, Shen S, Bai Y, Liu H. Recent advances in lipidomics for disease research. J Sep Sci. 2016;39(1):38–50.
Zhu Z, Qiu S, Shao K, Hou Y. Progress and challenges of sequencing and analyzing circulating tumor cells. Cell Biol Toxicol. 2017; 22.
Author information
Authors and Affiliations
Corresponding authors
Additional information
The original version of this article was revised due to a retrospective Open Access cancellation.
Rights and permissions
About this article
Cite this article
Zhang, L., Han, X. & Wang, X. Is the clinical lipidomics a potential goldmine?. Cell Biol Toxicol 34, 421–423 (2018). https://doi.org/10.1007/s10565-018-9441-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10565-018-9441-1